The two companies aim to collaborate on solutions providing early warnings, enabling the identification of patients that could otherwise go undiagnosed.
The company has also unveiled the Omron Blood Pressure Monitor + EKG, the first single at-home device in the U.S. that measures blood pressure and EKG.
Called MyGeneRank, the app allows users with genetic data from 23andMe to obtain an estimated genetic risk score for coronary artery disease.
The two parties have teamed-up to develop tools for medical and non-medical personnel to easily screen for congenital long QT syndrome (LQTS) early.
The platform is designed to help doctors monitor patients for the early detection of atrial fibrillation, which is the most common cardiac arrhythmia.
Called Q Heart, the application allows users to manually enter blood pressure readings or sync them from Apple's HealthKit, take notes and get trends.
MyCareLink Smart Monitor is comprised of a handheld portable device reader and the MyCareLink Smart mobile app, that works on iOS and Android devices.
The device-mobile app system records ECG, and can also measure Blood Oxygen Level and Heart Rate, as well as function as a pedometer.
The Hy-Result algorithm analyzes blood pressure data from in-home monitors to provide users with personalized assessments of their cardiovascular health.
Partners will develop the solution that combines AHA's science-based metrics with cognitive analytics, delivered on Welltok's health optimization platform.